The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Methods of producing bioconjugates of O-antigen polysaccharides covalently linked to a carrier protein using recombinant host cells are provided. The recombinant host cells used in the methods described herein encode a particular oligosaccharyl transferase enzyme depending on the O-antigen polysaccharide bioconjugate to be produced. The oligosaccharyl transferase enzymes can be PglB oligosaccharyl transferase or variants thereof. Also provided are compositions containing the bioconjugates, and methods of using the bioconjugates and compositions described herein to vaccinate a subject against extra-intestinal pathogenic E. coli. (ExPEC).

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

The present invention provides an ostrich antibody-containing composition for treating a bacterial infectious disease, and a method for treating a bacterial infectious disease by using the ostrich antibody. The present invention further provides a method for producing this ostrich antibody. The infectious disease can be a gastrointestinal infection. The ostrich antibody can be produced by using a component derived from a bacterium as an immunogen. The bacterium can be Clostridium difficile, Vibrio cholera, Staphylococcus aureus, or the like. Further, the bacterium can be a drug-resistant bacterium.

A composition for oral administration of a bioactive agent to aquatic or terrestrial species includes particles each of which includes a bioactive agent dispersed in oil droplets, the oil droplets being dispersed in a matrix including an enteric coating polymer, wherein the particles each further include a mucoadhesive polymer. Methods of making and using the composition are also provided.

A feed composition for preventing or treating acute hepatopancreatic necrosis disease (AHPND) or white spot syndrome (WSS), having a Bacillus subtilis (KCCM11143P) strain, a Bacillus pumilus (KCCM11144P) strain, and a Bacillus licheniformis (KCCM11270P) strain; culture media thereof; concentrates thereof; or dry matters thereof as an active ingredient. The feed composition exhibits antibacterial activity against Vibrio parahaemolyticus, which causes shrimp AHPND, and antiviral activity against white spot syndrome virus (WSSV), which causes WSS.

A feed composition for preventing or treating acute hepatopancreatic necrosis disease (AHPND) or white spot syndrome (WSS), having a Bacillus subtilis (KCCM11143P) strain, a culture medium thereof, a concentrate thereof, or a dry matter thereof as an active ingredient. The feed composition exhibits antibacterial activity against Vibrio parahaemolyticus causing shrimp AHPND and antiviral activity against white spot syndrome virus (WSSV) causing WSS.

The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

Vaccine vectors capable of eliciting an immune response to enteric bacteria and methods of using the same are provided. The vaccine vectors include a polynucleotide encoding a PAL polypeptide. The PAL polypeptide may be expressed on the surface of the vaccine vector. The vaccine vector may also include a second polypeptide encoding an immunostimulatory polypeptide such as a CD154 polypeptide or an HMGB1 polypeptide.

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.